Technology

32 Biosciences is a leader in gut microbiome health, offering the only clinically useful diagnostic tool to measure the functional health of the gut microbiome. Our solutions restore balance to the microbiome ecosystem, helping prevent and treat a wide range of diseases. 

Scientific Expertise

At 32 Biosciences, our approach is grounded in decades of visionary research led by our renowned scientific co-founders—John Alverdy, MD, Eugene Chang, MD, and Joseph Pierre, PhD. As globally recognized experts in microbiome science, their pathbreaking work includes over 650 peer-reviewed publications and $119M in NIH funding, forming the foundation of our innovative solutions.

Our transformative platform technologies are further propelled by strategic collaborations with the University of Chicago’s Duchossois Family Institute and Pritzker School of Molecular Engineering.

Our Solution: Two Pillars of Innovation

woman in white lab coat working

Diagnostic Management Platform

Our  Diagnostic Management Platform evaluates the gut microbiome’s functional health, using mass spectrometry to identify key metabolites, detected using advanced machine learning, that regulate critical cellular functions.

Designed for clinicians, this tool provides clinically actionable information to support the development of microbiome-based interventions (MBIs).

Therapeutics and Science-Based Nutritional Products

We are at the forefront of developing Microbiome-Based Interventions (MBIs), including FDA-approved therapies and scientifically validated nutritional solutions, all designed to optimize gut microbiome functional health. 

Leading our innovations is a potential first-of-its-kind, non-antibiotic antimicrobial therapeutic designed to prevent gut-derived bacterial infections by inhibiting virulence gene expression, enhancing the gut mucosal barrier, and promoting beneficial bacteria growth.

A person pouring powdered contents from a packet into a glass of water, with the background softly blurred and a blue hue overlay.